Cohn Leah A, DeClue Amy E, Cohen Rachael L, Reinero Carol R
University of Missouri, College of Veterinary Medicine, Department of Veterinary Medicine and Surgery, Columbia, MO, USA.
J Feline Med Surg. 2010 Feb;12(2):91-6. doi: 10.1016/j.jfms.2009.05.024. Epub 2009 Jul 31.
Cats with inflammatory bronchial disease are usually treated with glucocorticoid (GC) drugs to reduce airway inflammation. Inhalant GC delivery can preserve airway effects while systemic effects are minimized. An appropriate dosage regimen for inhaled GC in cats has not been investigated. A blinded, randomized, cross-over study design was used to investigate the ability of three different dosages of the inhalant GC fluticasone propionate delivered by metered dose inhaler to ameliorate eosinophilic airway inflammation in cats with experimentally induced allergic airway inflammation. Further, suppression of the hypothalamic-pituitary-adrenal axis (HPAA) at each dose was assessed. Fluticasone administered at dosages of 44, 110, or 220 microg q 12h reduced airway eosinophilia by 74%, 82%, or 81%, respectively (no difference). None of the dose regimens tested caused HPAA suppression. We conclude that a twice daily dosage of 44 microg fluticasone should be evaluated for the management of cats with naturally occurring inflammatory bronchial disease.
患有炎性支气管疾病的猫通常使用糖皮质激素（GC）药物进行治疗，以减轻气道炎症。吸入性GC给药可在将全身作用降至最低的同时保留气道效应。尚未对猫吸入性GC的合适给药方案进行研究。采用双盲、随机、交叉研究设计，研究通过定量吸入器递送的三种不同剂量的吸入性GC丙酸氟替卡松改善实验性诱导的变应性气道炎症猫的嗜酸性气道炎症的能力。此外，评估了每种剂量对下丘脑-垂体-肾上腺轴（HPAA）的抑制作用。以44、110或220微克每12小时的剂量给予氟替卡松，分别使气道嗜酸性粒细胞减少74%、82%或81%（无差异）。所测试的任何剂量方案均未导致HPAA抑制。我们得出结论，对于患有自然发生的炎性支气管疾病的猫，应评估每日两次44微克氟替卡松的给药方案用于治疗。
